ArticleExperimental and therapeutic medicine2017
The expression of insulin-like growth factor-1 in senior patients with diabetes and dementia.
Article in Experimental and therapeutic medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
- Diabetes Mellitus Should Be Considered While Analysing Sarcopenia-Related Biomarkers.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was conducted to investigate the expression of insulin-like growth factor-1 (IGF-1) in elderly patients with diabetes and dementia and to analyze the expression mechanism. A total of 30 senior patients with diabetes and dementia (group A), 30 senior patients with dementia but no diabetes (group B), 30 senior patients with diabetes but no dementia (group C), and 30 healthy seniors (group D) were continuously selected. The ELISA method was used to test the level of serum IGF-1, β-amyloid peptide (Aβ) and the phosphorylation of immunohistochemical staining of microtubule associated protein (tau protein). Western blot analysis was utilized to test the level of prion protein (PrP), forkhead transcription factor O (FOXO) subfamily protein, p-PI3K and p-Akt. The levels of IGF-1, Aβ, tau protein positive rate, PrP, FOXO protein, p-PI3K, and p-Akt in group A were significantly higher than that in group B, which was higher than in groups C and D. The results between groups A and B, but not groups C and D, were statistically significant (P<0.05). IGF-1 was highly expressed in senior patients with diabetes and dementia. Thus, IGF-1 can adjust the expression of PrP and FOXO through p-PI3K/Akt pathway and further impact the formation of Aβ and tau protein, leading to dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.